The International Centre for Professional Development In Health and Medicine (ICPDHM) – New Directions in Chronic Pain: What Might the Future Hold and the Role of Anti-Nerve Growth Factor
Thursday May 30, 0700-0800
This Section 1 accredited symposium will explore the unmet needs and challenges clinicians face in the pharmacological management of chronic pain, including limitations of current treatment options, treatment adherence, side effect management, and abuse/misuse potential. We will also review our evolving understanding of the pathophysiology of chronic pain, and how existing pharmacologic treatments modulate chronic pain pathways and mechanisms. Building on this science, we will discuss emerging pharmaceutical targets and the potential for mechanism-based treatments for chronic pain. Participants will gain an understanding of the mechanism of action of anti-nerve growth factor (NGF) drugs, and their possible clinical applications to help improve functional outcomes and quality of life for patients with chronic pain conditions, including osteoarthritis and chronic low back pain.
Learning Objectives: At the conclusion of this activity, participants will be able to:
- Identify unmet needs and challenges in the optimal treatment of chronic pain, including low back pain and osteoarthritis
- Explain the current understanding of pain pathways and mechanisms and how they are modulated by current pharmacological treatment options
- Describe the mechanism of action of anti-nerve growth factor drugs in the management of chronic pain and their potential application in the clinical setting
Dr. Jordi Perez, MD, PhD, FIPP, Associate Medical Director, Alan Edwards Pain Management Unit, McGill University Health Centre
Director, Cancer Pain Program, McGill University Health Centre
Associate Professor of Anesthesia, McGill University
Dr. Jordi Perez graduated in Medicine and then Anesthesiology in Barcelona, Spain and then pursued a career as pain clinician after a two-year combined research and clinical pain fellowship at McGill. He obtained his PhD with a research on dietary modifications and experimental neuropathic pain. He practiced pain medicine in Spain and England before rejoining McGill in 2012. He is currently Associate professor of Anesthesia at McGill University, directs the Cancer Pain Fellowship and is building the future McGill Pain Medicine Residency Program. Dr. Perez is Associate Medical Director of the Alan Edwards Pain Management Unit and Director of the MUHC Cancer Pain Program. As member of the McGill University Research Institute and the Alan Edwards Centre for Research on Pain, his research interests include cancer pain management, interventional procedures for the relief drug resistant pain and the role of methadone as alternative opioid analgesic for pain management.
Dr. Gordon Ko, MD, CCFP(EM), FCFP, FRCPC
Assistant Professor, Department of Medicine (Division of Physical Medicine & Rehabilitation), University of Toronto
Lecturer, Department of Rehabilitation Medicine (Division of Occupational Therapy), University of Toronto
Executive of the Section on Physical Medicine and Rehabilitation, Ontario Medical Association
Fellow, American Academy of Physical Medicine and Rehabilitation
American Association of Neuromuscular and Electrodiagnostic Medicine
Director, Canadian Association of Orthopaedic Medicine
Vice-President, Canadian Society for Neurotoxins in Pain
Dr. Gordon D. Ko is a specialist in Physical Medicine and Rehabilitation with subspecialty in Pain Medicine. He is Medical Director, Fibromyalgia Physiatry clinics and Adjunct Lecturer at Sunnybrook Health Sciences Centre, University of Toronto and the Canadian Centre for Integrative Medicine. In the latter, he leads an interdisciplinary team (PT,DC,DO,TCM,RD,ND) incorporating Functional Medicine and EMG/ultrasound-guided injection techniques. His research with Platelet-rich Plasma (PRP) for Back Pain and Botox injections for Knee Osteoarthritis made headline CTV national news. Available also on his website DrKoPRP.com are peer-reviewed papers including effective neuropathic pain treatment with Omega3, topical essential oils (RCT), medical cannabis (2016 review paper), PRP for low back pain and the 2012 Canadian guidelines for Fibromyalgia management. He enjoys teaching through non-profit organizations: Canadian Society for Neurotoxins in Pain (founding co-director/vice-president)-training MDs on Botox for pain and the Canadian Association for Orthopaedic Medicine (president-elect 2017-8)-prolotherapy and regenerative stem cell medicine.